期刊文献+

盐酸帕唑帕尼的合成 被引量:3

Synthesis of Pazopanib Hydrochloride
原文传递
导出
摘要 3-甲基-6-硝基-2H-吲唑(3)经甲基化、还原、单甲基化后,与2,4-二氯嘧啶缩合制得2,3-二甲基-N-(2-氯嘧啶-4-基)-N-甲基-2H-吲唑-6-胺,再与2-甲基-5-氨基苯磺酰胺经缩合、成盐酸盐制得抗肿瘤药盐酸帕唑帕尼,总收率约为37%。 Pazopanib hydrochloride was synthesized from 3-methyl-6-nitro-2H-indazole (3) by methylation, reduction, monomethylation and coupled with 2,4-dichloropyrimidine to give 2,3-dimethyl-N-(2-chloropyrimidin-4-yl)- N-methyl-2H-indazol-6-amine, which was condensed with 2-methyl-5-aminobenzene sulfonamide and then salt formation with an overall yield of about 37%.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第8期644-646,共3页 Chinese Journal of Pharmaceuticals
基金 国家“重大新药创制”科技重大专项(2009ZX09301-007)
关键词 盐酸帕唑帕尼 抗肿瘤药 合成 pazopanib hydrochloride antitumor agent synthesis
  • 相关文献

参考文献3

二级参考文献23

  • 1Drugs. New drug approvals [EB/OL]. ( 2010-1-1 ) [ 2010-1- 1]. http://www, drugs. com/newdrugs.html.
  • 2USA FDA. Drng Approval Reports [ EB/OL ]. (2010-1-1) [ 2010-1-1 ]. http://www. accessdata, fda. gov/scripts/cder/drug satfdal.
  • 3USA FDA. Vaccines, Blood & Biologic [ EB/OL ]. (2010-1-1) [ 2010-1-1 ]. http://www, fda. gov/BiologicsBloodVaccines/ default, htm.
  • 4European Medicines Agency. EPARs for authorised medicinal products for human use [ EB/OL ]. (2010-1-1) [ 2010-1-1 ]. http ://www. emea. europa, eu/htms/human/epar/a, htm.
  • 5国家食品药品监督管理局.国产药品(含包材)[EB/OL].(2003-4-17)[2010-1-1].http://appl.sfda.gov.cn/datasearch/face3/base.jsp?tableld=8&tableName:TABLE8&title=批准临床研究的新药&bcld=124356683643430217478147499292.
  • 6Niemann H, Kues WATransgenic farm animals: an update[J]. Reprod Fertil Dev, 2007, 19(6) :762 -770.
  • 7Dixon MB, Lien YH. Tolvaptan and its potential in the treatment of hyponatremia [J]. Ther Clin Risk Manag, 2008, 4 ( 6 ) : 1149 - 1155.
  • 8Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study [ J ]. Br J Anaesth, 2009, 102 (6) :785 -792.
  • 9Keating GM. Human Cl-esterase inhibitor concentrate(Berinert) [J]. Bio Drugs, 2009, 23(6) :399 -406.
  • 10Berntorp E, Windyga J, European Wilate Study Group. Treatment and prevention of acute bleedings in yon Willebrand disease-efficacy and safety of Wilate, a new generation yon Willebrand factor/factor Ⅷ concentrate[J]. Haemophilia, 2009, 15 (1) :122 -130.

共引文献20

同被引文献20

  • 1Sloan B,Sch einfeld N S.Pazopanib,a VEGF receptor tyrosinekinase inhibitor for cancer therapy[J].Curr Opin Investig Drugs,2008,9(12):1 324-1 335.
  • 2Harris P A,Boloor A,Cheung M,et al.Discovery of 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl benzenesulfonamide(Pazopanib),a novel andpotent vascular endothelial growth factor receptor inhibitor[J].J Med Chem,2008,51(15):4 632-4 640.
  • 3Sonpavde G, Hutson T E. Pazopanib: A novel multi- targeted tyrosine kinase inhibitor[ J]. Curr Oncol Rep, 2007,9(2) :115 - 119.
  • 4Sloan B, Scheinfeld N S. Pazopanib: A VEGF recep- tor tyrosine kinase inhibitor for cancer therapy [ J ]. Curt Opin Investig Drugs ,2008,9(12) :1324 -1335.
  • 5Boloor A, Cheung M. Chemical process [ P ]. WO 03 106 416,2003.
  • 6Whitehead B F, Ho P T, et al. Cancer treatment meth- od[P]. WO 2 007 143 483,2007.
  • 7Whittaker N, Jones, T S G. A new synthesis and the chemical properties of 5-aminopyfimidine [ J ]. J Chem Soc,1951,1565 - 1570.
  • 8Friesen D Y, Lorenz D A, Smith S W. Pharmaceutical compostions comprising an amorphous form ofa VEGF-R inhibitor [ P ]. WO: 2006123223, 2006-11-23.
  • 9Babu S, Dagnino R J, Ouellette M,et ol. Methods for preparing in- dazole compounds [ P ]. WO : 2006048745, 2006-05 - 11.
  • 10Harris PA, BOLOOR A, CHEUNG M, et al. Discovery of 5-[ [4- [ 2,3-dimethyl-2H-indazol-6-yl )methylamino ] -2-pyrimidinyl ] amino]-2-methyl-benzenesuffonamide (pazopanib),a nobel and potent vascular endothelial growth factor receptor inhibitor [ J ]. J Med.Chem., 2008,51 (7):4632-4640.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部